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ABSTRACT
Objectives: To establish the prevalence of ‘prostatic cancer after a previous prostatectomy
for benign prostatic hyperplasia (BPH)’ and to find out if there are any differences in clinical
presentation, histological characteristics and response to treatment, between this type of
cancer of prostate and that of prostatic cancer in patients with intact prostate.
Design: A prospective study carried out between January 1989 and December 1998.
Setting: University of Nigeria Teaching Hospital, Enugu and JAMA Urological Clinic in
Enugu, Nigeria .
Subjects: All patients presenting with histologically diagnosed carcinoma of the prostate
during the study period.
Interventions: Transperineal, transurethral and open prostatic biopsies. Hormonal
manipulations, transurethral prostatic resections, and ureteroneocystostomies.
Main outcome measures:  Clinical presentation, histological characteristics of the tumour,
and patient survival.
Results: Eight hundred and forty seven new cases of cancer of prostate were seen during the
study period and 39 of them had had prostatectomy for histologically diagnosed BPH in the
past (tissues were cut by step sectioning technique), giving a prevalence rate of 4.6%. Ages
of these 39 patients ranged from 64 to 89 years (mean 71.6 years), while that for the rest of
carcinoma of prostate ranged from 56 to 87 (mean 70.4 years). Time interval between
prostatectomy for BPH and presentation with prostatic cancer ranged from one  to 10 years
in 36 patients (mean 6.6 years) while the remaining three patients presented after 15, 20 and
22 years respectively. Histology in all the 847 patients showed adenocarcinoma. When the
two groups were compared, there were no statistically significant differences in clinical
presentation, histological grading, type of treatment and final outcome.
Conclusion: Prostatic carcinoma after prostatectomy for BPH is not uncommon. It should
be managed in the same line as those with cancer in intact prostate.
INTRODUCTION
The prostate gland is a major accessory sex gland in
the male that is prone to hyperplasia and neoplasia in
ageing men. It is separated by the urethra into ventral
fibromuscular and dorsal glandular portions(1,2). The
glandular portion is further divided into four zones - the
peripheral zone, the central zone, the transition zone and
the periurethral gland zone(1,2). There is a general
acceptance that carcinoma originates from the outer part
of the prostate while benign prostatic hyperplasia (BPH)
is usually found in the inner part of the gland(3).
Prostatectomy for BPH therefore does not confer immunity
against subsequent development of prostatic cancer
because, in the process of enucleating the adenoma, a
substantial but variable prostatic tissue including the
peripheral zone generally regarded as the carcinomatous
zone, is left behind. The first case of prostatic cancer after
prostatectomy for BPH was described in 1929 and many
more cases have since been described by other
workers(4-6). Low grade carcinomas arising from the
prostatic transition zone have also been described(7).
The epidemiology of prostate cancer is complex, with
few established risk factors(8-10). Worldwide, there has
been a dramatic increase in detection of prostatic cancer
since the introduction of prostate specific antigen (PSA)
test in the 1980’s(11). The incidence in China is less than
2 per 100,000 male population(12). In the United States of
America, the age adjusted rates in 1992 for black and
white men were 249 and 182 per 100,000 men
respectively(12). In Nigeria, a recent study showed the
hospital incidence to be 127 per 100,000 men(13), while
a startling incidence of 304 per 100,000 men was recorded
in Jamaica, the highest rate in the world(12).
The present study reviews the mode of presentation,
histological characteristics and treatment of prostatic cancer
occurring after prostatectomy for histologically diagnosed
BPH in comparison with prostatic cancer in patients with
intact prostates, in Enugu.
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MATERIALS AND METHODS
Between January 1989 and December 1998, all new cases
of cancer of the prostate that presented to two busy health
establishments in Enugu metropolis - University of Nigeria
Teaching Hospital and JAMA Urological Clinic, were studied.
The diagnosis of carcinoma of prostate was reached after history,
physical examination including digital rectal examination (DRE),
relevant investigations including serum electrolytes, urea and
creatinine, serum acid phosphatase, skeletal survey, trans-
abdominal ultrasonography and prostatic biopsy (transperineal
or transurethral, and open biopsies in those whose bladders were
explored incidentally). All the cases of carcinoma of the prostate
after previous prostatectomy for BPH had their original slides
reviewed by our pathologists before being classified as such.
When the original slides of the cases of carcinoma of prostate
after prostatectomy were reviewed, those in two patients revealed
suspicious areas of prostatic cancer and these were promptly
excluded from this category. Out of all the 847 patients with
clinical prostate cancer, 21(2.5%) presented with incidental
cancer. Serum prostate specific antigen (PSA) and transrectal
ultrasonography (TRUS) were not done as these facilities were
not available at the time of study. All the patients were started on
treatment and reviewed monthly for as long as possible. From
this total number of carcinoma of prostate, those who had had
prostatectomy for histologically diagnosed BPH in the past,
were identified and their features compared with the rest of the
prostate cancers with intact prostate. The variables collected and
compared were age, clinical presentation, tumour stage and
grade, treatment methods and outcome. Also noted was the
interval between prostatectomy for BPH and presentation with
cancer of the prostate. Tumour staging was by modified Whitmore
method(14) and the grading system was according to Mostofi(15).
In the unclassified group, the histological differentiation was not
stated. Chi-square analysis of the variables in the two groups was
done by Computer using the Epi Info  Version 5 Software.
RESULTS
During the study period, 847 new cases of
histologically diagnosed carcinoma of the prostate were
encountered. Out of these, 39 patients had had
prostatectomy for histologically diagnosed BPH in the
past. This gives a prevalence rate of 4.6% for this type of
prostatic cancer. The ages of these 39 men ranged from 64
to 86 years (mean 71.6 years) while that for the rest of
carcinoma of prostate with intact prostate was from 56 to
87 years (mean 70.4 years).
Table 1 shows the clinical presentation compared in
the two groups of patients. Raised erythrocyte
sedimentation rate (ESR) was present in all the patients.
Metastatic symptoms and signs included lower back pains,
paraplegia, haemoptysis, palpably enlarged abdominal
and supraclavicular lymph nodes, visible metastases to
skull and chest wall. One hundred and two patients first
presented with symptoms and signs of renal failure as a
result of obstructive nephropathy. In 31 patients, the
clinical diagnosis was suspected on routine examination
by physicians for general ill health. Statistical analysis of
the clinical features at presentation showed no significant
difference in the two groups of prostatic cancer patients
(Chi-square = 13.1 , DF = 8, P value = 0.09).
Table 1
Clinical presentation
Presentation Post-prostatectomy Carcinoma in Total
carcinoma intact prostate No. (%)
Number (%) Number (%)
Raised ESR 39 (100.0) 808 (100.0) 847 (100.0)
Abnormal digital
    rectal examination 32 (82.1) 756 (93.6) 788 (93.0)
Irritative symptoms 34 (87.2) 714 (88.4) 748 (88.3)
Weight loss 35 (89.7) 687 (85.0) 722 (85.2)
Dysuria 19 (48.7) 489 (60.5) 508 (60.0)
Haematuria 28 (71.8) 457 (56.6) 485 (57.3)
Metastatic signs
    and symptoms 16 (41.0) 391 (48.4) 407 (98.1)
Chronic constipation 16 (41.0) 343 (42.5) 359 (42.4)
Urinary retention 17 (43.6) 278 (34.4) 295 (34.8)
Renal impairment 6 (15.4) 96 (11.9) 102 (12.0)
Incidental finding 5 (12.8) 26 (3.2) 31 (3.7)
Chi square=13.71, DF=8, p value=0.09
Table 2 shows the interval between prostatectomy for
BPH and presentation of carcinoma of prostate in 39
patients. Thirty six patients (92.3%) presented within 10
years of the prostatectomy with a mean of 6.6 years.
Among these, ten showed mild anaplasia, eleven moderate
anaplasia and five marked anaplasia, while in ten, the
histological differentiation was not classified.
Table 2
Interval between prostatectomy for BPH and presentation with
prostatic cancer






>10 (15, 20 and 22 years
respectively) 3 7.7
The remaining three patients presented at 15, 20 and 22
years respectively. Table 3 shows the clinical stage of the
tumour at presentation in all the patients. Three patients
who had had prostatectomy in the past for BPH, presented
with enlarged prostates after  8, 10 and 15 years respectively.
Digital rectal examination and available investigations
pointed to the benign nature of the recurrent growths and
these shelled out very well at open prostatectomy. However,
histology showed foci of carcinoma. Generally, patients
with cancer of the prostate presented more with late stage
disease. When the stage at presentation in the two groups
were compared statistically (Chi-square = 6.48, DF = 3
and P value = 0.09), there was no significant difference.
Similarly Table 4 shows the histological grading in the
two groups, and when compared (Chi-square = 5.4, DF =
3 and P value = 0.11), there was no significant difference.
In 122 patients, the histological differentiation was not
stated (unclassified).
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Table 3
Clinical stage at presentation (Whitmore)
Stage Carcinoma after Carcinoma in intact
prostatectomy  (n=39) prostate  (n=808)
Number (%) Number (%)
A 3 (7.7) 18 (2.2)
B 2 (5.1) 76 (9.4)
C 14 (35.9) 228 (28.2)
D 20 (51.3) 486 (60.1)
Chi square = 6.48, DF = 3, P value = 0.09
Table 4
Histological grading of tumours (Mostofi)
Histological grade Carcinoma after Carcinoma in
prostatectomy intact  prostate
Number (%) Number (%)
Grade I (mild anaplasia) 10 (25.6) 282 (34.9)
Grade II (moderate anaplasia) 12 (30.8) 203 (25.1)
Grade III (marked anaplasia) 7 (17.9) 211 (26.1)
Unclassified 10 (25.6) 112 (13.9)
Chi square = 5.94, DF = 3, P value = 0.11
Table 5 shows the mode of treatment in the two
groups of patients. Hormonal manipulation was the sole
mode of treatment in 643 patients (75.9%). In the remaining
204 patients (24.1%), in addition to hormonal manipulation,
other modes of treatment were employed. Hormonal
manipulations included bilateral orchidectomy and drugs
like stilbestrol, cyproterone acetate, flutamide,
bicalutamide and leutinising hormone releasing hormone
analogues, depending on what the patient could afford.
Ureteroneocystostomy was added when the patient
presented with obstructive uropathy secondary to
obstruction of the lower end of the ureters by the tumour.
Table 5
Type of treatment
Type of treatment Carcinoma after Carcinoma in Total
prostatectomy intact prostate
Number (%) Number (%) No. (%)
Hormonal
manipulation alone 24 (61.5) 619 (76.6) 643 (75.9)
Hormonal manipulation
+ TURP 10 (25.6) 146 (18.1) 156 (18.4)
Hormonal manipulation
+ Uretero-
neocystostomy 3 (7.7) 34 (4.2) 37 (4.4)
Hormonal manipulation
+ TURP + uretero-
neocystostomy 2 (5.1) 9 (1.1) 11 (1.3)
Total 39 808 847
Chi square = 7.92, DF = 3, P value = 0.05 (borderline)
Generally, most patients were followed up for one
year, thereafter, follow up was very irregular. In the 39
patients with cancer of prostate after prostatectomy for
BPH, 28 were alive at the end of one year, eight were
reported dead while three were lost to follow up. In the 808
patients with cancer in the intact prostate, 416 were alive
at the end of one year, 98 were reported dead while 294
were lost to follow up.
DISCUSSION
We have presented 847 new cases of cancer of prostate
whom we saw over a period of ten years. Out of these, 39
patients have previously had prostatectomy for
histologically diagnosed BPH. This gives a prevalence
rate of this type of cancer of the prostate (cancer of prostate
after prostatectomy for BPH) to be 4.6% which compares
with a figure of five per cent  in a similar study by Schwartz
et al(5). It was not possible to deduce from this study the
impact, if any, prostatectomy for BPH had on the risk for
subsequent development of prostatic cancer. This would
entail follow up of the same number of age-matched
control with histologically proven BPH for the same
period and determining the incidence of prostatic cancer
in the two groups. Two previous studies on this gave
conflicting results(16). However, during our ten-year  study
period, a total of 1419 prostatectomies were done for
histologically diagnosed BPH. If it is assumed that
approximately this number is done every ten years, a
rough incidence of 2.7% of occurrence of cancer of
prostate after prostatectomy for BPH would be deduced
from this study, which  compares with 2.0% of Schwartz
et al(5) and 0.4 -8.7% of Armenian et al(l7).
We are aware that lack of thoroughness in the
examination of the enucleated prostatic specimen after the
original prostatectomy for BPH, could lead to a missed
cancer of the prostate at the time of the original surgery.
This error was minimised by the review of the original
slides by our pathologists before inclusion.
The mean age at presentation in the patients with
cancer of the prostate after a previous prostatectomy for
BPH was similar to that for patients with intact prostate -
71.6 years and 70.4 years respectively. Also, the clinical
presentation was not different in the two groups. The
patients who presented solely with waist pains had received
various treatments for arthritis at some peripheral hospitals
without improvement before presenting to us. This pattern
of presentation was also observed by Osegbe(13) in a
study on prostate cancers in Nigerians.
The earliest time of presentation of cancer of prostate
after prostatectomy for BPH was 16 months while the
longest interval was 22 years. Thirty six patients presented
within ten years of prostatectomy with a mean interval of
6.6 years while only three patients presented after an
interval of more than ten years. Schwartz et al(5) noted
two patterns on examination of the interval between
prostatectomy for BPH and diagnosis of prostatic cancer.
They noted that ten patients (50%) had cancer diagnosed
within four years and another 10 patients (50%) had
prostatic cancer diagnosed between seven and 28 years
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after prostatectomy for BPH. It is assumed that these
cancerous lesions arose from the peripheral zone since the
adenoma had been enucleated. Previous studies on small
prostate cancers concluded that non-hypertrophied senile
tissue and sclerotic atrophic glands outside the expanding
nodules of hypertrophy are sites of origin of the
carcinoma(3). The different time intervals of presentation
after prostatectomy for BPH could be explained by
Eschenbach trilogy(18). This postulates that: (a) the tumour
can remain indolent throughout the patient’s lifetime and
never progress  to clinically significant disease; (b) that the
tumour grows slowly and remains confined within the
prostate for an ample time to allow for detection and; (c)
that ab nitio, the tumour is virulent and invasive in
biological behaviour, thus manifesting early. All the poorly
differentiated tumours in this study were in stages C and
D. However, there was no relationship between the
histological grading of the tumour and the interval between
the time of prostatectomy and presentation with cancer,
thus emphasising the diverse nature in malignant expression
of prostatic cancer. This was also noted by Schwartz et
al(5).
When the patients with cancer of prostate after previous
prostatectomy were compared with the other patients with
carcinoma in the intact prostate, with regards to the stage
at presentation, it was observed that most patients (87.2%
and 88.3% respectively) presented late with stages C and
D disease. A similar late presentation of carcinoma of
prostate in Nigerians was observed by Osegbe(13) who
noted that 86.4% of cases presented late. However, this
contrasted with a figure of 40 - 50% in Europe and 20% in
USA reported by Newling(19). This is no doubt due to
increased health awareness and better diagnostic facilities
in these developed countries.
The grade of the tumour at presentation in patients
who had had prostatectomy for BPH was similar to those
who had intact prostate. The poorly differentiated tumours
were in stages C and D as noted above. Fowler et al(20)
noted that locally advanced prostate cancers are often
poorly differentiated with about 50% associated with
regional lymph node metastasis. This same pattern also
featured in African American males who presented
clinically with higher prostate specific antigen levels,
tumours of greater stage, grade and volume, early in the
disease(21).
All the patients were subjected to hormonal
manipulations. This stems from the work of Huggins and
Hodges(22,23) emphasising the hormone dependence of
prostatic cancer. All the patients benefitted initially from
the therapy. The regression in the tumour experienced by
all the patients is attributable to androgen deprivation.
Civantos et al(24) noted some architectural pattern changes
in the prostate as a result of androgen deprivation which
include decrease in size and density of neoplastic glands
associated with increased stroma between the dispersed
small glands. Another pattern noted by the same workers
included branching clefts lined by a few scattered tumour
cells with pyknotic nuclei and degenerated tumour cells
with foamy vacuolated cytoplasm. None of these patterns
was confirmed in our patients since no repeated prostatic
biopsy was done after the commencement of treatment.
Long term follow up was difficult in most of our
patients. In the majority of cases, follow up was very
irregular after one year and even in the first year, a good
number of patients were lost to follow up. This same
pattern had earlier been observed and the probable reasons
outlined, in a previous study on bladder tumours in Enugu,
Nigeria(25).
In conclusion, prostatic cancer after prostatectomy
for histologically diagnosed BPH is not uncommon. The
pattern of presentation is the same as in those who have not
had an earlier prostatectomy. Patients who present with
micturition problems or backache after prostatectomy for
BPH should be fully re-evaluated. Primary hormonal
manipulation is a reasonably safe and rewarding treatment
option in the elderly with this type of cancer who may have
a significant comorbid disease that may require therapeutic
intervention.
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Letter to the Editor-in-Chief
Dear Sir,
CONCEPTUAL BASIS OF 'EARLY' AND 'DELAYED' REINFECTION WITH PLASMODIUM FALCIPARUM
When a female anopheline mosquito carrying sporozoites
in her salivary glands feeds on a human, sporozoites pass
into the bloodstream. Some of these sporozoites are
transported to the liver, where they invade the hepatocytes,
initiating the cycle that culminates into malarial disease.
When sporozoites have been injected into the human
bloodstream, various factors (for example, time) determine
the development of the disease. Such studies have been
conducted in western Kenya to determine whether the
levels of naturally acquired antibodies to circumsporozoites
proteins would be predictive of protection against P.
falciparum infection during a 98-day period when the rate
of malaria transmission was high. In the study, 93 adult
males, life long residents of Saradidi donated blood
samples for malaria parasite smears. Each volunteer was
then treated with a single dose of three tablets of
pyrimethamine-sulfadoxine (Fansidar, Roche), followed
by 100 mg of doxycycline twice daily for seven days. On
the basis of local parasite susceptibility to fansidar alone,
radical cures were expected for all volunteers. Each
volunteer was visited for the next 96 days and blood
smears were analysed on days 7, 14, 28, 42, 56, 70, 84
and 98 and any other day a volunteer complained of
illness. Eighty two volunteers completed the study. Thirty
two of the 82 (39%) had P. falciparum on day 0. None
was positive on day 7, 14 or 28. Between day 42 and
96 there was a gradual increase in the cumulative
proportion with parasitaemia. By day 96, 60 (75%) had
become positive.
The study group (96 adults) had all life-long, intense
exposure to malaria, yet 75% had P. falciparum re-
infection within 96 days after radical cure of infection.
Twenty two (25%) did not develop re-infection after 96
days. Thus, the 75% of the volunteers who developed re-
infection within 96 days can be referred to as “early re-
infected” group whereas the 25% who did not develop
re-infection within the study period can be classified as
“delayed re-infected” group.
Yours sincerely
J.B.L. Chek, MSc, PhD, Senior Lecturer, and K. Werimo, Department
of Biochemistry, University of Nairobi, P.O. Box 30197, Nairobi.
